Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Jan 13, 2020

Journey Medical Corporation Recaps 2019 Growth

Jan 13, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders

Dec 23, 2019

Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol

Dec 11, 2019

Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

Dec 09, 2019

Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference

Dec 02, 2019

Fortress Biotech to Participate in December 2019 Investor Conferences

Dec 02, 2019

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

Nov 25, 2019

Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

Nov 20, 2019

Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

Nov 19, 2019